At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Nivolumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Cisplatin, and 2 other interventions for Head and Neck Cancer. Completed, enrolled 6 participants across 4 sites.
Detailed Summary
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartJun 2019
Primary CompletionOct 2022
Study CompletionDec 2022
TodayJul 2026
First PostedMar 29, 2019
Enrollment StartJun 11, 2019
Primary CompletionOct 31, 2022
Study CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.3 years ago
Interventions
Nivolumabdrug
Nivolumab is a type of immunotherapy.
Cisplatindrug
Cisplatin is a chemotherapy drug.
Docetaxeldrug
Docetaxel is a chemotherapy drug.
Intensity-modulated radiotherapyradiation
IMRT is definitive treatment for head and neck cancer.